Closed Loop Technologies Clinical and Behavioral Approaches to Improve Type 1 Diabetes Outcomes (R01) | Apply Online

Opportunity Summary:

The NIH funding opportunity titled "Closed Loop Technologies Clinical and Behavioral Approaches to Improve Type 1 Diabetes Outcomes (R01)" (Funding Opportunity Number RFA-DK-08-012) supported research projects aimed at moving "artificial pancreas" style systems closer to practical, real-world use for people with type 1 diabetes. The program was offered jointly by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). Its central focus was on human-subject studies that link continuous glucose monitoring (CGM) to insulin delivery in a closed loop arrangement, with an emphasis on making these systems highly reliable and easy to operate. A key point of the announcement is that only human studies were considered responsive, meaning proposals limited to animal work, bench testing alone, or purely engineering simulations without human testing would not meet the intent of the call.

From a research perspective, the opportunity was built around three connected goals. First, it sought studies that tackle behavioral factors that limit adoption and sustained use of closed loop systems. This includes practical issues such as user trust in automation, alarm fatigue, burden of device maintenance, willingness to wear multiple components, comfort with calibration and troubleshooting, and how patients and families make day-to-day decisions when a device is partly or fully automating insulin dosing. In other words, the NIH was signaling that technical performance alone is not enough; successful closed loop care also depends on human behavior, preferences, training, and real-life usability across different ages and settings.

Second, the FOA encouraged investigators to use closed loop and related technologies as research tools to deepen understanding of the physiology and pathophysiology of glucose regulation in type 1 diabetes. That framing supports projects where closed loop data streams, automated insulin adjustments, and controlled glycemic experiments in people can reveal new insights into glucose dynamics, insulin sensitivity variation, counterregulatory responses, meal and exercise effects, and sources of glycemic variability. The intent was not only to build better devices, but also to learn more about how glucose regulation behaves in real humans under different conditions, and to use that knowledge to improve algorithms and clinical approaches.

Third, the program explicitly called for studies that test and improve the safety, reliability, and utility of closed loop technologies in humans. That includes work that strengthens performance under challenging conditions such as exercise, illness, variable meal composition, missed boluses, infusion set problems, sensor inaccuracies, or communication failures between components. It also includes improving system safeguards to reduce hypoglycemia risk, handle sensor errors, and ensure predictable behavior when devices fail or data are missing. The overall outcomes NIH wanted to see were better metabolic control with fewer and smaller glucose excursions, more flexibility in daily living (for example, around meals, sleep, travel, and activity), and improved quality of life for people living with type 1 diabetes.

Administratively, this was an R01 Research Project Grant, meaning it was designed for substantial, hypothesis-driven or goal-driven research projects rather than small pilot efforts. The announcement listed an estimated total funding amount of $5.5 million, with an award ceiling of $500,000 (as provided in the source information). Cost sharing or matching was not required. The opportunity was posted on December 8, 2008, and closed on March 19, 2009, with an archive date of April 19, 2009.

Eligibility was broad and included many organization types. Eligible applicants included public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations (including those with and without 501(c)(3) status), for-profit organizations other than small businesses, and small businesses. It also included state governments, U.S. territories or possessions, and a range of tribal entities (federally recognized tribal governments as well as other tribal organizations and tribally controlled colleges and universities). The NIH also highlighted additional eligible applicant categories such as historically Black colleges and universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, faith-based or community-based organizations, regional organizations, and non-U.S. entities (foreign organizations). Program areas were aligned with CFDA numbers 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research) and 93.865 (Child Health and Human Development Extramural Research), reflecting the joint institute sponsorship and the relevance to both diabetes outcomes and pediatric/family health contexts.

In practical terms, this FOA targeted multidisciplinary teams that could combine clinical diabetes expertise, behavioral science, human factors engineering, device and algorithm development, and rigorous human research methods. The strongest-fit projects would have been those that not only demonstrate technical closed loop performance in people, but also address why and how people actually use these systems, how to make them safer and more robust in daily life, and how human closed loop experimentation can reveal insights that feed back into better therapies and better outcomes.

Browse more business programs for Diabetes Research

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Food and Nutrition Health Income Security and Social Services

Next opportunity: Closed Loop Technologies Pilot and Exploratory Clinical and Behavioral Approaches to Improve Type 1 Diabetes Outcomes (R21)

Previous opportunity: Central Nervous System Intersections of Drug Addiction, Chronic Pain and Analgesia (R01)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA DK 08 012

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (RFA DK 08 012) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA DK 08 012", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.